|
Synonyms: arginine-rich, mutated in early stage tumors-like 1 | ARMETL1
Compound class:
Endogenous peptide in human, mouse or rat
Comment: CDNF is a dopamine neuron neurotropic factor [5]. It provides cytoprotective effects in neurodegenerative disease models by reducing the activating effect of endoplasmic reticulum stress on the unfolded protein response (UPR) pathway [4,7]. Specifically, CDNF has been shown to protect dopamine neurons and improve motor function in animal Parkinson's disease models [1-2,5-6,8]. However therapeutic use of proteins like CDNF is invasive (intracranial administration) and requires clinical expertise.
Species: Human
|
| No information available. |
Summary of Clinical Use  |
| The effect of centrally administered CDNF has been investigated in human volunteers with Parkinson's disease [3]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03775538 | Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study | Phase 1/Phase 2 Interventional | Herantis Pharma Plc. | ||
| NCT03295786 | Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease | Phase 1/Phase 2 Interventional | Herantis Pharma Plc. | ||
| NCT04228653 | Long-Term Follow-up Safety After DDS Implantation With/Without CDNF Infusions | Phase 1/Phase 2 Interventional | Renishaw | ||
